Karen Walker currently serves as a strategic advisor on technical operations activities, having previously served as Chief Technology Officer at Kyverna Therapeutics. Ms. Walker has broad and deep industry experience developing biopharmaceuticals and cell and gene therapy (CGT) products. She brings extensive and pioneering expertise in the product development, manufacturing, and supply of cell-based therapies and associated analytics.
Ms. Walker has several decades of biotech industry experience, holding positions in Technical Development, Regulatory Affairs, and Quality at a number of companies including Roche/Genentech, Seattle Genetics, Novartis, Amgen, Bayer, Bristol-Myers Squibb, and several other small to mid-sized biotech companies. She comes to Kyverna from Roche/Genentech where she was Senior Advisor, Cell and Gene Therapy Manufacturing. In this position, she was instrumental in developing and implementing the strategy for CGT manufacturing and controls into the Roche/Genentech organization.
Prior to Roche/Genentech, Ms. Walker was Vice President of Global Quality at Seagen Inc., formerly Seattle Genetics, where she oversaw and directed the Global Quality Organization in the U.S. and Europe. Previously, she was Vice President and Global Head of Cell and Gene Therapy Technical Development and Manufacturing for Novartis’ CGT Unit. There, she led the Chemistry, Manufacturing, and Controls (CMC) teams through the formation of the strategies and execution of those strategies to develop KYMRIAH® (tisagenlecleucel) through the pivotal trial stage and to filing of the first CAR-T Biologics License Application (BLA) in pediatric acute lymphoblastic leukemia (ALL). During her time at Novartis and continuing to the present, Ms. Walker has been a strong and leading voice in the establishment of industry standardization and contributed to influence emerging regulatory guidances in the area of CGT products globally.
Ms. Walker holds a bachelor’s degree from St. Olaf College. She is a member of numerous pharmaceutical industry trade organizations, including the Alliance for Regenerative Medicines (ARM) Cell Therapy Manufacturing Committee, DeLoitte Industry Working Group for Advanced Therapy Medicinal Products (ATMPs), Parenteral Drug Association (PDA), PDA Biologics Advisory Board, where she was vice chair from 2018 to 2020, and the PDA ATMP Working Group.
What is Karen Marie Walker's net worth?
The estimated net worth of Karen Marie Walker is at least $224.78 thousand as of December 15th, 2025. Ms. Walker owns 22,636 shares of Kyverna Therapeutics stock worth more than $224,775 as of April 17th. This net worth evaluation does not reflect any other investments that Ms. Walker may own. Learn More about Karen Marie Walker's net worth.
How do I contact Karen Marie Walker?
Has Karen Marie Walker been buying or selling shares of Kyverna Therapeutics?
Karen Marie Walker has not been actively trading shares of Kyverna Therapeutics in the last ninety days. Most recently, Karen Marie Walker sold 23,998 shares of the business's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $12.20, for a transaction totalling $292,775.60. Following the completion of the sale, the chief technology officer now directly owns 22,636 shares of the company's stock, valued at $276,159.20. Learn More on Karen Marie Walker's trading history.
Who are Kyverna Therapeutics' active insiders?
Are insiders buying or selling shares of Kyverna Therapeutics?
During the last twelve months, Kyverna Therapeutics insiders bought shares 2 times. They purchased a total of 266,666 shares worth more than $1,999,995.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 23,998 shares worth more than $292,775.60. The most recent insider tranaction occured on December, 18th when Director Beth C Seidenberg bought 133,333 shares worth more than $999,997.50. Insiders at Kyverna Therapeutics own 22.0% of the company.
Learn More about insider trades at Kyverna Therapeutics. Information on this page was last updated on 12/18/2025.
